Have a feature idea you'd love to see implemented?
Let us know!
DAWN Day One Biopharmaceuticals Inc
Price (delayed)
$13.34
Market cap
$1.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.03
Enterprise value
$925.14M
Highlights
The company's equity has surged by 81% QoQ and by 43% YoY
The company's EPS has surged by 55% YoY and by 47% QoQ
The quick ratio has contracted by 14% YoY
Key stats
What are the main financial stats of DAWN
Market
Valuations
Earnings
Shares outstanding
100.85M
Market cap
$1.35B
Enterprise value
$925.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.11
Price to sales (P/S)
12.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.07
Revenue
$101.95M
EBIT
-$83.62M
EBITDA
-$82.25M
Free cash flow
$17.77M
Per share
Balance sheet
Liquidity
EPS
-$1.03
Free cash flow per share
$0.18
Book value per share
$6.33
Revenue per share
$1.06
TBVPS
$6.05
Total assets
$600.81M
Total liabilities
$45.34M
Debt
$2.62M
Equity
$555.46M
Working capital
$541.25M
Debt to equity
0
Current ratio
14.62
Quick ratio
14.27
Net debt/EBITDA
5.11
Margins
Efficiency
Dividend
EBITDA margin
-80.7%
Gross margin
97.7%
Net margin
-82.7%
Operating margin
-207.4%
Return on assets
-19.8%
Return on equity
-22.4%
Return on invested capital
-105.2%
Return on capital employed
-14.9%
Return on sales
-82%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DAWN stock price
How has the Day One Biopharmaceuticals stock price performed over time
Intraday
-2.06%
1 week
-6.84%
1 month
-10.65%
1 year
11.91%
YTD
-8.63%
QTD
-4.24%
Financial performance
How have Day One Biopharmaceuticals's revenue and profit performed over time
Revenue
$101.95M
Gross profit
$99.66M
Operating income
-$211.46M
Net income
-$84.29M
Gross margin
97.7%
Net margin
-82.7%
The net margin has surged by 96% since the previous quarter
Day One Biopharmaceuticals's operating margin has surged by 94% QoQ
DAWN's net income has surged by 52% year-on-year and by 50% since the previous quarter
The operating income has increased by 28% from the previous quarter but it has decreased by 12% YoY
Growth
What is Day One Biopharmaceuticals's growth rate over time
Valuation
What is Day One Biopharmaceuticals stock price valuation
P/E
N/A
P/B
2.11
P/S
12.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.07
The company's EPS has surged by 55% YoY and by 47% QoQ
The company's equity has surged by 81% QoQ and by 43% YoY
The stock's P/B is 43% less than its last 4 quarters average of 3.7
Efficiency
How efficient is Day One Biopharmaceuticals business performance
The company's return on sales has surged by 96% QoQ
The ROA has soared by 56% year-on-year and by 55% since the previous quarter
Day One Biopharmaceuticals's ROE has soared by 55% from the previous quarter and by 54% YoY
The ROIC has grown by 46% from the previous quarter but it has contracted by 34% YoY
Dividends
What is DAWN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DAWN.
Financial health
How did Day One Biopharmaceuticals financials performed over time
Day One Biopharmaceuticals's total liabilities has surged by 85% YoY but it has shrunk by 52% QoQ
DAWN's total assets has soared by 50% since the previous quarter and by 45% year-on-year
The debt is 100% smaller than the equity
The company's equity has surged by 81% QoQ and by 43% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.